Signature of the Host Response to a Respiratory Viral Infection, in the Prediction of Bronchiolitis Obliterans

Recruiting Observational Study
Allogeneic Hematopoietic Stem Cell Recipients Acute Respiratory Infection Parainfluenza Virus (PIV)
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
14 (estimated)
Sponsor
Assistance Publique - Hôpitaux de Paris · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Bronchiolitis obliterans (BO) is the well-known manifestation of the chronic pulmonary graft-versus-host disease(GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). The pathophysiology of BO is, however, poorly known. The available data strongly support the role of respiratory viruses, in particular paramyxoviruses (parainfluenzae virus (PIV), respiratory syncytial virus, metapn…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria : * Adults having received a hematopoietic stem cell transplantation for less than two years * Availability of respiratory function tests prior to infection * Presence of PIV respiratory infection documented by identification of the virus by PCR in the upper and/or lower respirat…
Contacts

David Michonneau, MD PhD

1 42 49 49 49

david.michonneau@aphp.fr

CONTACT

Jérôme Lambert, MD PhD

142499742

jerome.lambert@u-paris.fr

CONTACT